Is the frequency of crossfit practice correlated with stress urinary incontinence? a transversal study of prevalence / A frequência da prática de crossfit está correlacionada com a incontinência urinária de esforço? um estudo transversal de prevalência

Mirella Dias, Vitória Laura de Melo, Letícia Ferreira, Suellen Cristina Roussenq, Juliana Lenzi, Joana Moreira dos Santos, Ana Patricia Dubón, Fabiana Flores Sperandio, Carolina Barreto Mozzini


Objective: To verify the prevalence of SUI symptoms in practitioners of high intensity physical activities, such as CrossFit, and to analyze the correlation of the high frequency of this activity with urinary losses, in a CrossFit gym in Greater Florianópolis - SC. Methods: This is a cross-sectional study in which the sample was composed of women who had practiced the CrossFit modality for over a month and over 18 years of age. A questionnaire was applied to assess the data regarding personal characteristics, reproductive life, training frequency and Crossfit time, perceptions about urine loss and evaluation by the Pad-test. Results: The final sample was 34 women, the average age of the participants was 30.3 ± 6.43 years. Among them, 76.4% were nulliparous, 61.7% had been practicing the sport for at least 8 months, 14% reported perceiving urine loss on a daily basis and 88.2% had stress urinary incontinence characterized as mild to moderate. A correlation of greater urinary loss was found the greater the frequency of weekly training Conclusion: Most of the women participating presented urine loss on exertion, classified as mild to moderate. Demonstrating that high intensity activities, such as Crossfit, and their weekly frequency can directly influence stress urinary incontinence. There is a need for further research with a larger sample, greater homogeneity of training and individualization in the evaluation.


Urinary incontinence, Exercise, Woman

Full Text:



Gonçalves BM, Sirqueira SC, Aires RS, Sampaio MC, Barbosa JR, Lopes AF, Godoi DR. Treatment of chronic Hepatitis C with daclatasvir, sofosbuvir and simeprevir in patients from the reference hospital of infectology in central Brazil. Brazilian Journal of Development. 2021;7(4): 34017-30.

Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172-82.

Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol. 2012;2012:980942.

Negoi I, Paun S, Hostiuc S, Stoica B, Tanase I, Negoi RI, et al. Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo). 2015;13(4):500-5.

Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13:1099.

Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol Hematol. 2015;93(3):246-56.

Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol. 2015;7(3):327-43.

Stübgen JP. Immune-mediated myelitis associated with hepatitis virus infections. J Neuroimmunol. 2011;239(1-2):21-7.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21(8):2269-80.

Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145-60.

Russi S, Sansonno L, Sansonno D. Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges. Curr Drug Targets. 2017;18(7):766-71.



  • There are currently no refbacks.